--- title: "CITIC International raised the target price of WuXi Biologics to 39 yuan and maintained a \"Buy\" rating" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/280718086.md" description: "CMB International has raised the target price for WuXi Biologics to 39 yuan and maintained a \"Buy\" rating. The report pointed out that WuXi Biologics' revenue grew by 16.7% last year, and adjusted net profit increased by 17.9%, both exceeding expectations. It is expected that this year's revenue will grow by 13% to 17%, and may be higher due to foreign exchange fluctuations. Revenue and adjusted net profit are expected to continue to grow over the next three years" datetime: "2026-03-27T02:17:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280718086.md) - [en](https://longbridge.com/en/news/280718086.md) - [zh-HK](https://longbridge.com/zh-HK/news/280718086.md) --- > 支持的语言: [English](https://longbridge.com/en/news/280718086.md) | [繁體中文](https://longbridge.com/zh-HK/news/280718086.md) # CITIC International raised the target price of WuXi Biologics to 39 yuan and maintained a "Buy" rating CMB International published a research report indicating that WuXi Biologics (02269.HK) had a revenue growth of 16.7% year-on-year last year, with adjusted net profit increasing by 17.9% year-on-year, exceeding the bank's forecasts by 1.2% and 9.6%, respectively. According to preliminary guidance from management, revenue is expected to grow by 13% to 17% this year, and if excluding the potential impact of foreign exchange fluctuations, the growth rate is expected to be even higher. The bank stated that the visibility of WuXi Biologics' growth has improved, raising the company's target price from HKD 35.6 to HKD 39, maintaining a "Buy" rating. The bank expects the company's revenue to grow by 14.6%, 16.3%, and 15% year-on-year from 2026 to 2028, while adjusted net profit is expected to increase by 18.7%, 17.4%, and 13.6% during the same period ### 相关股票 - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-CN/quote/588130.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-CN/quote/159506.CN.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-CN/quote/159615.CN.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-CN/quote/159102.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-CN/quote/512290.CN.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-CN/quote/588250.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-CN/quote/513120.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-CN/quote/159849.CN.md) - [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-CN/quote/513700.CN.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md) - [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-CN/quote/159992.CN.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-CN/quote/159316.CN.md) - [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-CN/quote/510660.CN.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-CN/quote/520880.CN.md) - [Direxion S&P Biotech Bull 3X (LABU.US)](https://longbridge.com/zh-CN/quote/LABU.US.md) - [WuXi Biologics (WXXWY.US)](https://longbridge.com/zh-CN/quote/WXXWY.US.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-CN/quote/159892.CN.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-CN/quote/159859.CN.md) - [WUXI BIO (02269.HK)](https://longbridge.com/zh-CN/quote/02269.HK.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-CN/quote/588860.CN.md) ## 相关资讯与研究 - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-CN/news/281054154.md) - [UCB presents new Bimzelx data at AAD](https://longbridge.com/zh-CN/news/280813909.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-CN/news/281231901.md) - [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/zh-CN/news/280992698.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-CN/news/281458440.md)